{"classes":[{"categories":[{"measurements":[{"comment":"Data could not be calculated due to insufficient number of events.","groupId":"OG000","lowerLimit":"1.807","upperLimit":"NA","value":"4.14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Duration of overall response (CR, CRc, CRh, CRi, and PR) was defined as time from first response to time of relapse or death from any cause, whichever came first. CR, CRc, and CRh, CRi, and PR as defined in Outcome Measure 21 above.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received IMGN632 via IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Total R/R BPDCN Participants - Schedule A: IMGN632 0.045 mg/kg"}],"paramType":"MEDIAN","populationDescription":"mITT Population included all participants who were eligible based on the screening criteria and who received at least 1 dose of study drug. Here, 'Overall number of participants analyzed' = Total R/R BPDCN participants with overall response. Per protocol, this endpoint evaluated only total R/R BPDCN participants with overall response, all of whom were in arm Schedule A: IMGN632 0.045 mg/kg.","reportingStatus":"POSTED","timeFrame":"Up to approximately 81 months","title":"Duration of Overall Response As Assessed by Investigator in Total R/R BPDCN Participants","type":"SECONDARY","unitOfMeasure":"months"}